Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: Clinicopathological correlation

Oncologist

Volumn 13, Issue 4, 2008, Pages 451-458

  Lucas, David R ^a,d   Kshirsagar, Malti P ^a   Biermann, J Sybil ^b   Hamre, Merlin R ^c   Thomas, Dafydd G ^a   Schuetze, Scott M ^a   Bakerd, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Drug therapy; Neoadjuvant therapy; Pathology; Sarcoma; Soft tissue neoplasms

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT INFORMATION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TISSUE DEGENERATION; TISSUE REACTION; TISSUE SECTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; SARCOMA; TREATMENT OUTCOME;

EID: 43549098481     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0220     Document Type: Article

References (29)

1. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-1654.
2. Zalupski MM, Baker LH. Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematol Oncol Clin North Am 1995;9:787-800.
3. Rouesse JG, Friedman S, Sevin DM et al. Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer 1987;60:296-300.
4. Zunino JH, Johnston JO. Prognostic value of histologic tumor necrosis assessment in osteogenic sarcoma of bone. Am J Orthop 2000;29:369-372.
5. Raymond AK, Chawla SP, Carrasco CH et al. Osteosarcoma chemotherapy effect: A prognostic factor. Semin Diagn Pathol 1987;4:212-236.
6. Picci P, Sangiorgi L, Rougraff BT et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-2705.
7. Picci P, Rougraff BT, Bacci G et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993;11:1763-1769.
8. Picci P, Bohling T, Bacci G et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol 1997;15:1553-1559.
9. Bacci G, Mercuri M, Longhi A et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005;41:2079-2085.
10. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112-128.
11. Zalupski MM, Rankin C, Ryan JR et al. Adjuvant therapy of osteosarcoma - a phase II trial: Southwest Oncology Group study 9139. Cancer 2004;100:818-825.
12. Menendez LR, Ahlmann ER, Savage K et al. Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma. Clin Orthop Relat Res 2007;455:219-224.
13. Henshaw RM, Priebat DA, Perry DJ et al. Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol 2001;8:484-495.
14. Eilber FC, Rosen G, Eckardt J et al. Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001;19:3203-3209.
15. Pezzi CM, Pollock RE, Evans HL et al. Preoperative chemotherapy for softtissue sarcomas of the extremities. Ann Surg 1990;211:476-481.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005;23:105-112.
18. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976;60:1749-1760.
19. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-1492.
20. Picci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985;56:1515-1521.
21. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14-18.
22. Ayala AG, Raymond AK, Jaffe N. The pathologist's role in the diagnosis and treatment of osteosarcoma in children. Hum Pathol 1984;15:258-266.
23. Schmidt RA, Conrad EU 3rd, Collins C et al. Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 1993;72:2593-2601.
24. Kraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006;24:619-625.
25. Jimenez RE, Zalupski MM, Frank JJ et al. Multidrug resistance phenotype in high grade soft tissue sarcoma: Correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer 1999;86:976-981.
26. Coffin CM, Lowichik A, Zhou H. Treatment effects in pediatric soft tissue and bone tumors: Practical considerations for the pathologist. Am J Clin Pathol 2005;123:75-90.
27. Casper ES, Gaynor JJ, Harrison LB et al. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994;73:1644-1651.
28. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369-373.
29. Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-578.